Two Biodesix directors resign effective May 20, 2025; Schuler named director emeritus

BIODESIX INC

Charles Watts, M.D. resigns from Board and Compensation Committee effective at 2025 Annual Meeting (May 20, 2025).
Jack Schuler resigns from Board and Nominating & Corporate Governance Committee, transitions to director emeritus (non-voting advisory role).
Both resignations not due to any disagreement with Company's operations, policies, or practices.
Dr. Watts served since July 2019; Mr. Schuler served since June 2008.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles Watts, M.D.

Director

BDSX · BIODESIX INC

Effective: 2025-05-20
Filed: April 17, 2025, 7:59 PM ET

On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Watts, M.D. resigned as Director at BIODESIX INC.

Action: resigned
Role: Director

Exact text from the filing

On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.

View on SEC.gov

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0001193125-25-084319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.